| Assessment Status | Rapid review complete |
| HTA ID | 22030 |
| Drug | Dapagliflozin |
| Brand | Forxiga® |
| Indication | Indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. |
| Assessment Process | |
| Rapid review commissioned | 09/05/2022 |
| Rapid review completed | 03/06/2022 |
| Rapid review outcome | A full HTA s not recommended. The NCPE recommends that dapagliflozin be considered for reimbursement* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
